Dietary Nucleotides in Dogs Undergoing Anticancer Chemotherapy

Study title

Dietary Nucleotides in Dogs Undergoing Anticancer Chemotherapy

Purpose of study

The purpose of this study is to determine whether the addition of dietary nucleotides alters immune responses in dogs undergoing chemotherapy for lymphoma and osteosarcoma.

Background

Chemotherapy for treatment of canine cancers generally has systemic effects as evidenced by cytopenias, depressed immune function, and variable disruption of the gastrointestinal barrier. There is some evidence that dietary administration of nucleotides can ameliorate the adverse affects of chemotherapy and possibly improve response and/or patient tolerance to the chemotherapeutic agents.

Inclusion criteria

Dogs recently diagnosed with either lymphoma or osteosarcoma and undergoing standard chemotherapy are eligible for this double-blind, placebo-controlled study.

Study Design

Dogs will be diagnosed and staged according to standard of practice. Baseline evaluations will include a complete blood count, serum biochemical profile, urinalysis, and immune function studies. They will then be randomized to receive either nucleotides or placebo in addition to their chemotherapeutic treatments. All patients will be monitored weekly at OSU; at weeks 4 and 8, blood and immune function tests will be repeated and evidence of GI barrier disruption, as measured by urinary levels of intestinal fatty acid-binding protein and other GI tissue analytes, will be evaluated and compared to baseline measurements.

Client Compensation

Each client will receive a discount of $200.00 applied toward their hospital bill.

For more information on this study, please contact Dr. Guillermo Couto, at (614) 292-3551 or via clinicaltrials [at] cvm [dot] osu [dot] edu.